These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 29377987)

  • 1. Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes.
    Ellermann C; Sterneberg M; Kochhäuser S; Dechering DG; Fehr M; Eckardt L; Frommeyer G
    Europace; 2018 Oct; 20(10):1699-1706. PubMed ID: 29377987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad antiarrhythmic effect of mexiletine in different arrhythmia models.
    Frommeyer G; Garthmann J; Ellermann C; Dechering DG; Kochhäuser S; Reinke F; Köbe J; Wasmer K; Eckardt L
    Europace; 2018 Aug; 20(8):1375-1381. PubMed ID: 29016765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ryanodine-receptor inhibition by dantrolene effectively suppresses ventricular arrhythmias in an ex vivo model of long-QT syndrome.
    Frommeyer G; Krawczyk J; Ellermann C; Bögeholz N; Kochhäuser S; Dechering DG; Fehr M; Eckardt L
    J Cardiovasc Electrophysiol; 2018 Mar; 29(3):471-476. PubMed ID: 29314443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivabradine Aggravates the Proarrhythmic Risk in Experimental Models of Long QT Syndrome.
    Frommeyer G; Weller J; Ellermann C; Leitz P; Kochhäuser S; Lange PS; Dechering DG; Eckardt L
    Cardiovasc Toxicol; 2019 Apr; 19(2):129-135. PubMed ID: 30238354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome.
    Frommeyer G; Ellermann C; Dechering DG; Kochhäuser S; Bögeholz N; Güner F; Leitz P; Pott C; Eckardt L
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1214-1219. PubMed ID: 27283775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiarrhythmic properties of ivabradine in an experimental model of Short-QT- Syndrome.
    Frommeyer G; Weller J; Ellermann C; Kaese S; Kochhäuser S; Lange PS; Dechering DG; Eckardt L
    Clin Exp Pharmacol Physiol; 2017 Sep; 44(9):941-945. PubMed ID: 28556923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent antiarrhythmic effects of resveratrol and piceatannol in a whole-heart model of long QT syndrome.
    Ellermann C; Wolfes J; Kochhäuser S; Dechering DG; Reinke F; Wasmer K; Eckardt L; Frommeyer G
    Int J Cardiol; 2017 Sep; 243():233-238. PubMed ID: 28606656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
    Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
    J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the Na+/Ca2+ exchanger suppresses torsades de pointes in an intact heart model of long QT syndrome-2 and long QT syndrome-3.
    Milberg P; Pott C; Fink M; Frommeyer G; Matsuda T; Baba A; Osada N; Breithardt G; Noble D; Eckardt L
    Heart Rhythm; 2008 Oct; 5(10):1444-52. PubMed ID: 18929333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents.
    Frommeyer G; Fischer C; Ellermann C; Dechering DG; Kochhäuser S; Lange PS; Wasmer K; Fehr M; Eckardt L
    Cardiovasc Toxicol; 2018 Feb; 18(1):84-90. PubMed ID: 28612303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.
    Milberg P; Ramtin S; Mönnig G; Osada N; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Pharmacol; 2004 Sep; 44(3):278-86. PubMed ID: 15475823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome.
    Shimizu W; McMahon B; Antzelevitch C
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):154-64. PubMed ID: 10090218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propofol abolishes torsade de pointes in different models of acquired long QT syndrome.
    Ellermann C; Könemann H; Wolfes J; Rath B; Wegner FK; Willy K; Dechering DG; Reinke F; Eckardt L; Frommeyer G
    Sci Rep; 2020 Jul; 10(1):12133. PubMed ID: 32699382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiarrhythmic effect of vernakalant in an experimental model of Long-QT-syndrome.
    Frommeyer G; Clauss C; Ellermann C; Bogossian H; Dechering DG; Kochhäuser S; Reinke F; Pott C; Eckardt L
    Europace; 2017 May; 19(5):866-873. PubMed ID: 27702859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disturbances of cardiac wavelength and repolarization precede Torsade de Pointes and ventricular fibrillation in Langendorff perfused rabbit hearts.
    Hondeghem LM
    Prog Biophys Mol Biol; 2016 May; 121(1):3-10. PubMed ID: 26980523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
    Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
    J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.